Can Koyuncu

Can Koyuncu

Auto-generated profile, based on publicly available information

Can Koyuncu

Department of Biomedical Engineering, Case Western Reserve University, Cleveland, OH, USA

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2021 in Cancer Research
Verified
Journal Article
Open access
PDF file
WXWeisi Xie
Weisi Xie
NRNicholas P. Reder
Nicholas P. Reder
CKCan F Koyuncu
Can F Koyuncu
PLPatrick Leo
Patrick Leo
SHSarah Hawley
Sarah Hawley
JLJonathan Liu
Jonathan Liu
Prostate cancer treatment planning is largely dependent upon examination of core-needle biopsies. The microscopic architecture of the prostate glands forms the basis for prognostic grading by pathologists. Interpretation of these convoluted three-dimensional (3D) glandular structures via visual inspection of a limited number of two-dimensional (2D) histology sections is often unreliable, which contributes to the under- and overtreatment of patients. To improve risk assessment and treatment decisions, we have developed a workflow for nondestructive 3D pathology and computational analysis of whole prostate biopsies labeled with a rapid and inexpensive fluorescent analogue of standard hematoxylin and eosin (H&E) staining. This analysis is based on interpretable glandular features and is facilitated by the development of image translation–assisted segmentation in 3D (ITAS3D). ITAS3D is a generalizable deep learning–based strategy that enables tissue microstructures to be volumetrically segmented in an annotation-free and objective (biomarker-based) manner without requiring immunolabeling. As a preliminary demonstration of the translational value of a computational 3D versus a computational 2D pathology approach, we imaged 300 ex vivo biopsies extracted from 50 archived radical prostatectomy specimens, of which, 118 biopsies contained cancer. The 3D glandular features in cancer biopsies were superior to corresponding 2D features for risk stratification of patients with low- to intermediate-risk prostate cancer based on their clinical biochemical recurrence outcomes. The results of this study support the use of computational 3D pathology for guiding the clinical management of prostate cancer. Significance: An end-to-end pipeline for deep learning–assisted computational 3D histology analysis of whole prostate biopsies shows that nondestructive 3D pathology has the potential to enable superior prognostic stratification of patients with prostate cancer.

3 June 2022 in Science Advances
Verified
Journal Article
Closed access
Xiangxue WangXiangxue Wang
Xiangxue Wang
CBCristian Barrera
Cristian Barrera
KBKaustav Bera
Kaustav Bera
VVVidya Sankar Viswanathan
Vidya Sankar Viswanathan
SASepideh Azarianpour-Esfahani
Sepideh Azarianpour-Esfahani
Anant MadabhushiAnant Madabhushi
Anant Madabhushi
Immune checkpoint inhibitors (ICIs) show prominent clinical activity across multiple advanced tumors. However, less than half of patients respond even after molecule-based selection. Thus, improved biomarkers are required. In this study, we use an image analysis to capture morphologic attributes relating to the spatial interaction and architecture of tumor cells and tumor-infiltrating lymphocytes (TILs) from digitized H&E images. We evaluate the association of image features with progression-free (PFS) and overall survival in non–small cell lung cancer (NSCLC) ( N = 187) and gynecological cancer ( N = 39) patients treated with ICIs. We demonstrated that the classifier trained with NSCLC alone was associated with PFS in independent NSCLC cohorts and also in gynecological cancer. The classifier was also associated with clinical outcome independent of clinical factors. Moreover, the classifier was associated with PFS even with low PD-L1 expression. These findings suggest that image analysis can be used to predict clinical end points in patients receiving ICI.

1 February 2021 in Medical Image Analysis
Verified
Journal Article
Closed access
CLCheng Lu
Cheng Lu
CKCan Koyuncu
Can Koyuncu
GCGerman Corredor
German Corredor
PPPrateek Prasanna
Prateek Prasanna
PLPatrick Leo
Patrick Leo
Anant MadabhushiAnant Madabhushi
Anant Madabhushi

29 November 2021 in JNCI: Journal of the National Cancer Institute
Verified
Journal Article
Open access
PDF file
GCGermán Corredor
Germán Corredor
PTPaula Toro
Paula Toro
CKCan Koyuncu
Can Koyuncu
CLCheng Lu
Cheng Lu
CBChristina Buzzy
Christina Buzzy
Anant MadabhushiAnant Madabhushi
Anant Madabhushi
Human papillomavirus (HPV)–associated oropharyngeal squamous cell carcinoma (OPSCC) has excellent control rates compared to nonvirally associated OPSCC. Multiple trials are actively testing whether de-escalation of treatment intensity for these patients can maintain oncologic equipoise while reducing treatment-related toxicity. We have developed OP-TIL, a biomarker that characterizes the spatial interplay between tumor-infiltrating lymphocytes (TILs) and surrounding cells in histology images. Herein, we sought to test whether OP-TIL can segregate stage I HPV-associated OPSCC patients into low-risk and high-risk groups and aid in patient selection for de-escalation clinical trials. Association between OP-TIL and patient outcome was explored on whole slide hematoxylin and eosin images from 439 stage I HPV-associated OPSCC patients across 6 institutional cohorts. One institutional cohort (n = 94) was used to identify the most prognostic features and train a Cox regression model to predict risk of recurrence and death. Survival analysis was used to validate the algorithm as a biomarker of recurrence or death in the remaining 5 cohorts (n = 345). All statistical tests were 2-sided. OP-TIL separated stage I HPV-associated OPSCC patients with 30 or less pack-year smoking history into low-risk (2-year disease-free survival [DFS] = 94.2%; 5-year DFS = 88.4%) and high-risk (2-year DFS = 82.5%; 5-year DFS = 74.2%) groups (hazard ratio = 2.56, 95% confidence interval = 1.52 to 4.32; P < .001), even after adjusting for age, smoking status, T and N classification, and treatment modality on multivariate analysis for DFS (hazard ratio = 2.27, 95% confidence interval = 1.32 to 3.94; P = .003). OP-TIL can identify stage I HPV-associated OPSCC patients likely to be poor candidates for treatment de-escalation. Following validation on previously completed multi-institutional clinical trials, OP-TIL has the potential to be a biomarker, beyond clinical stage and HPV status, that can be used clinically to optimize patient selection for de-escalation.

26 May 2023 in The Journal of Pathology
Verified
Journal Article
Closed access
RSRobert Serafin
Robert Serafin
CKCan Koyuncu
Can Koyuncu
WXWeisi Xie
Weisi Xie
HHHongyi Huang
Hongyi Huang
AGAdam K Glaser
Adam K Glaser
JLJonathan Liu
Jonathan Liu

19 February 2022 in Laboratory Investigation
Verified
Journal Article
Closed access
DWDavid C. Wilde
David C. Wilde
PCPatricia D. Castro
Patricia D. Castro
KBKaustav Bera
Kaustav Bera
SLSyeling Lai
Syeling Lai
Anant MadabhushiAnant Madabhushi
Anant Madabhushi
VSVlad Sandulache
Vlad Sandulache